Saturday, July 11, 2026

pharma · Leukemia, Lymphocytic, Acute, B-Cell · Prostate Cancer Indications

Shenzhen Second People's

Shenzhen Second People's is a pharma organization headquartered in CN. Primary therapeutic focus areas include Leukemia, Lymphocytic, Acute, B-Cell, Prostate Cancer Indications. NovaPharmaNews links 2 clinical program(s)

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
2
Drugs
4
Patents
0
Clinical program

Immunomodulatory DC vaccines to target prostate cancer

Phase 2 · mab · Prostate Cancer Indications

Immunomodulatory DC vaccines to target prostate cancer for Prostate Cancer Indications is a Phase 2 program (mab) at Shenzhen Second People's Hospital with 1 ClinicalTrials.gov record(s).

Internal code GIMI-IRB-25002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Shenzhen Second People's Hospital
Phase
Phase 2
Modality
mab
Indication
Prostate Cancer Indications
Status
active
Trials
1